Results 81 to 90 of about 2,668 (112)

Continuous infusion of meropenem-vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance. [PDF]

Infection, 2023
Larcher R, Laffont-Lozes P, Naciri T, Bourgeois PM, Gandon C, Magnan C, Pantel A, Sotto A.   +7 more
europepmc   +1 more source

Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase. [PDF]

JAC Antimicrob Resist, 2023
Bovo F, Amadesi S, Palombo M, Lazzarotto T, Ambretti S, Gaibani P.   +5 more
europepmc   +1 more source

Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy. [PDF]

Antimicrob Agents Chemother
Reed G, Valadez A, Smith BJ, McCreary EK, Kline EG, Neely MN, Squires KM, Shields RK, Rhodes NJ.   +8 more
europepmc   +1 more source

Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections- results from a retrospective multicentre study. [PDF]

Infection
Marino A, Maraolo AE, Mazzitelli M, Oliva A, Geremia N, De Vito A, Gullotta C, Scaglione V, Vania E, Lo Menzo S, Navalesi P, Volpicelli L, Fiori A, Prestifilippo P, Cattelan A, Mastroianni CM, Madeddu G, Cacopardo B, Nunnari G.   +18 more
europepmc   +1 more source

Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms

Infectious Diseases and Therapy, 2018
Sarah C. J. Jorgensen, Michael J. Rybak
doaj   +1 more source

TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient. [PDF]

J Antimicrob Chemother
Mulé G, Coniglione G, Gatti M, Cona A, Di Martino G, Ranucci G, de Ville de Goyet J, Pea F, Mularoni A.   +8 more
europepmc   +1 more source

A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae. [PDF]

Antimicrob Agents Chemother
Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, Perez F, Hujer AM, Hujer KM, van Duin D, Fowler V, Chambers HF, Kreiswirth BN, Bonomo RA, Antibacterial Resistance Leadership Group.   +14 more
europepmc   +1 more source

Comparative Outcomes of Meropenem-Vaborbactam vs. Ceftazidime-Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021. [PDF]

Antibiotics (Basel)
Zilberberg MD, Nathanson BH, Redell MA, Sulham K, Shorr AF.   +4 more
europepmc   +1 more source

Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients. [PDF]

J Antimicrob Chemother
Gatti M, Rinaldi M, Laici C, Ambretti S, Siniscalchi A, Viale P, Pea F.   +6 more
europepmc   +1 more source

Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study. [PDF]

Open Forum Infect Dis
Tumbarello M, Raffaelli F, Giannella M, De Pascale G, Cascio A, De Rosa FG, Cattelan AM, Oliva A, Saracino A, Bassetti M, Mussini C, Luzzati R, Capone A, Signorini L, Bartoletti M, Sambo M, Sarmati L, Antinori S, Mularoni A, Tascini C, Corona A, Pascale R, Rubino R, Corcione S, Mazzitelli M, Giuliano G, Lovecchio A, Bavaro DF, Meschiari M, Montagnani F, Fabbiani M, De Benedetto I, Antonelli M, Venditti M, Viale P.   +34 more
europepmc   +1 more source